Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in HIV-Infected Patients

Background:This study assessed the safety and efficacy of intradermal injections of polylactic acid (PLA) in patients with facial lipoatrophy under antiretroviral therapy. Methods:In a prospective open-label study, PLA was injected in both cheeks every 2 weeks. The primary efficacy endpoint was the patient's self-perception of improvement as assessed by a visual analogue scale (VAS). Secondary endpoints included 3-dimensional photographs (3DP) to measure dermal thickness, quality of life (QoL) scores, and adverse events. Results:Ninety-four patients received a median of 5 sets of injection in both cheeks. Median age was 43 years, and median CD4 cell count was 500/mm3. Median VAS score significantly increased from 3.4/10 at baseline to 6.8/10 at the end of the treatment procedure and was sustained at 7/10 at the end of follow-up (P < 0.0001 vs. baseline). Median dermal thickness increase was 2.3 mm at the end of follow-up. QoL scores remained unchanged. Seventeen patients needed further injections of PLA during a median follow-up of 12 months. Injections were well tolerated with only 1 serious adverse event (anaphylactic reaction) that necessitated treatment interruption. Conclusions:Injections of PLA improved patients' self-perception of facial lipoatrophy, with a good safety profile. The benefit of the procedure, however, decreased with time.

[1]  L. Lysakova,et al.  A randomized open‐label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection , 2004, HIV medicine.

[2]  D. Cooper,et al.  No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[3]  Philippe Katz,et al.  Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA , 2003, AIDS.

[4]  A. Bircher,et al.  Anaphylaxis to the Carbohydrate Carboxymethylcellulose in Parenteral Corticosteroid Preparations , 2003, Dermatology.

[5]  P. Yeni,et al.  Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial , 2002, AIDS.

[6]  J. Carruthers,et al.  HIV‐Associated Facial Lipoatrophy , 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  M. Mimoun,et al.  Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. , 2002, AIDS.

[8]  D. Cooper,et al.  Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. , 2002, JAMA.

[9]  J. Ragnaud,et al.  Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  P. Morlat,et al.  Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Moatti,et al.  Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy , 2001, AIDS.

[12]  R. Paredes,et al.  Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor‐Experienced Patients With HIV‐Associated Lipodystrophy: 1‐Year Prospective Follow‐Up of a Multicenter, Randomized, Controlled Study , 2001, Journal of acquired immune deficiency syndromes.

[13]  Ignacio Conget,et al.  Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study , 2001, The Lancet.

[14]  M. Ritt,et al.  Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. , 2001, Acta chirurgiae plasticae.

[15]  J. Gatell,et al.  Lipodystrophy Syndrome in Patients with HIV Infection , 2001, Drug safety.

[16]  O. Böstman,et al.  Bioabsorbable fixation in orthopaedic surgery and traumatology. , 2000, Biomaterials.

[17]  J. Currier How to manage metabolic complications of HIV therapy: what to do while we wait for answers. , 2000, The AIDS reader.

[18]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[19]  Morris Schambelan,et al.  “Buffalo hump” in men with HIV-1 infection , 1998, The Lancet.

[20]  M. Olenius The First Clinical Study Using a New Biodegradable Implant for the Treatment of Lips, Wrinkles, and Folds , 1998, Aesthetic Plastic Surgery.

[21]  B. Wüthrich,et al.  Peranaesthetic anaphylactoid shock due to mannitol , 1992, Allergy.

[22]  H. Rubin,et al.  A Health Status Questionnaire Using 30 Items From The Medical Outcomes Study: Preliminary Validation in Persons With Early HIV Infection , 1991, Medical care.

[23]  P. Törmälä,et al.  Absorption, biocompatibility, and fixation properties of polylactic acid in bone tissue: an experimental study in rats. , 1991, Clinical orthopaedics and related research.

[24]  Richard L. Kronenthal,et al.  BIODEGRADABLE POLYMERS IN MEDICINE AND SURGERY , 1975 .